Revive Therapeutics advances bucillamine patents

Executive Summary

• Revive Therapeutics Ltd. has achieved two significant intellectual property milestones for its bucillamine franchise: the filing of U.S. and Canadian national phase patent applications for the use of bucillamine in treating victims exposed to chemical warfare agents, and the grant of a Canadian patent for the treatment of infectious diseases.
• The newly granted Canadian Patent No. 3,172,170 covers methods and uses of bucillamine for treating or preventing infectious diseases, including influenza and COVID-19, and expires on March 16, 2041.
• The new patent filings and grants strengthen Revive’s long-term exclusivity and strategic positioning in medical countermeasures, government preparedness, and infectious disease markets, supporting ongoing research collaborations with Defence R&D Canada (DRDC).

Key Details

• U.S. and Canadian Patent Filings (Chemical Warfare):
  • Filed under PCT/CA2024/000008 for "Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent."
  • U.S. Application Number: 19/518,001.
  • Canadian Application Number: 3,304,264.
• Canadian Patent Grant (Infectious Diseases):
  • Patent No.: 3,172,170.
  • Title: "Use of Bucillamine in the Treatment of Infectious Diseases."
  • Grant Date: March 10, 2026.
  • Expiration Date: March 16, 2041.
  • Scope: Covers methods and uses for treatment or prevention of infectious diseases, specifically citing influenza and COVID-19.
• Strategic Context and Applications:
  • The filings broaden Revive's position in medical countermeasures, including government preparedness, emergency response, and stockpiling programs for chemical and biological threats.
  • Additional potential applications identified for bucillamine include organophosphate pesticide poisoning, traumatic brain injury, viral infections, and long COVID.
• Ongoing Research:
  • Active research collaboration with Defence R&D Canada -- Suffield Research Centre (DRDC).
  • DRDC is evaluating bucillamine for mitigating nerve agent-induced brain injury.
  • The Bucillamine research study with DRDC is expected to conclude shortly, with results to be released only with DRDC authorization.
• Asset Background:
  • Bucillamine is a thiol-based drug with over 30 years of clinical use in rheumatoid arthritis in Japan and South Korea.
  • Described as significantly more effective than NAC as an antioxidant, with potential neuroprotection in nerve-agent exposure models.
  • Mechanism involves donating thiols, replenishing glutathione, activating the Nrf2 pathway, and preserving GABA(A) receptor function.

Notable Quotes

• "The grant of our Canadian patent for infectious diseases and the advancement of our nerve-agent patent filings in the U.S. and Canada represent a major step forward for Revive and for the long-term value of bucillamine. We believe these milestones validate bucillamine as a versatile platform asset with the potential to address significant unmet needs in infectious diseases, public-health emergencies and government-funded medical countermeasures." — Michael Frank, CEO
• "We believe Revive is building a highly strategic bucillamine franchise with meaningful upside. With patent protection now strengthened in infectious diseases, new patent filings advancing in nerve-agent exposure and ongoing work with DRDC, we are increasingly positioned to pursue value across therapeutic, public-health and national-preparedness markets. Bucillamine is not a one-indication story -- it is a platform opportunity." — Michael Frank, CEO